Recent studies demonstrated that retinoids with high affinity for specific isoforms of RAR (RAR isoform-specific retinoids)30,31 or RARγ agonist retinoids32 are endowed with superior activity than ATRA in non-APL, AML treatment, due to the ability to induce differentiation in all the population of AML. This evidence concerns the gene RARA and acute myeloid leukemia.